Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
2.01B | 1.99B | 1.97B | 1.91B | 1.73B | Gross Profit |
2.01B | 421.56M | 467.03M | 513.24M | 449.32M | EBIT |
-68.71M | 7.32M | 172.69M | 202.92M | 173.52M | EBITDA |
-28.37M | 29.89M | 235.64M | 249.88M | 200.37M | Net Income Common Stockholders |
-103.61M | -60.41M | 66.33M | 130.96M | -9.58M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
348.51M | 177.74M | 9.82M | 387.39M | 1.23B | Total Assets |
2.15B | 2.22B | 2.35B | 2.72B | 3.35B | Total Debt |
662.31M | 701.65M | 753.57M | 1.07B | 1.80B | Net Debt |
432.37M | 628.39M | 743.74M | 678.44M | 680.87M | Total Liabilities |
1.39B | 1.37B | 1.46B | 1.83B | 2.60B | Stockholders Equity |
764.94M | 849.06M | 891.63M | 896.69M | 747.72M |
Cash Flow | Free Cash Flow | |||
184.55M | 104.00M | 137.23M | 44.49M | 175.83M | Operating Cash Flow |
206.57M | 137.32M | 166.94M | 76.74M | 204.62M | Investing Cash Flow |
-35.41M | -48.18M | -56.95M | -53.07M | 815.51M | Financing Cash Flow |
-14.48M | -25.71M | -487.55M | -760.12M | -4.16M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $887.50M | 36.15 | 10.40% | ― | 27.59% | 61.97% | |
68 Neutral | $1.46B | 14.45 | 10.79% | 2.58% | 15.25% | 51.77% | |
65 Neutral | $1.07B | 37.86 | 5.75% | 2.54% | 11.00% | 37.38% | |
57 Neutral | $1.25B | ― | -65.55% | ― | 3.95% | -5.53% | |
51 Neutral | $5.32B | 3.32 | -40.25% | 2.90% | 17.93% | 2.14% | |
49 Neutral | $1.07B | ― | -12.28% | ― | 0.92% | -65.03% | |
44 Neutral | $891.58M | ― | 42.49% | ― | 6.82% | 92.03% |
On January 12, 2025, Pediatrix Medical Group appointed Mark S. Ordan as Chief Executive Officer, replacing Dr. James D. Swift. Mr. Ordan’s appointment includes an employment agreement with a detailed compensation package, highlighting the company’s strategic leadership transition and potential impact on its corporate governance and market positioning.